Hong Kong IPO disclosure precedents · 28 companies, 28 items
Disclosures highlighting a narrowing or improving trend of operating cash outflows across periods, together with cash management or improvement measures.
Our net cash generated from operating activities was RMB136.4 million and RMB235.9 million in 2023 and 2024, respectively, as compared to our net cash used in operating activities of RMB1.1 billion in 2022, primarily due to the improvement of profitability.
Financial Information · p. 411
In terms of cash flows, we pivoted to generating positive net operating cash flow in 2023 and 2024 from a state of negative net operating cash flow in 2022.
Our net cash used in operating activities amounted to RMB562.1 million, RMB936.3 million, RMB593.6 million, RMB240.9 million and RMB155.5 million, respectively, in 2021, 2022, 2023 and the six months ended June 30, 2023 and 2024.
Summary · p. 2
Our net cash used in operating activities experienced significant improvements, decreasing from RMB936.3 million in 2022 to RMB593.6 million in 2023, and from RMB240.9 million in the six months ended June 30, 2023 to RMB155.5 million in the six months ended June 30, 2024.
Business · p. 291
With our expecting business scale, growing economies of scale, improving operating efficiency and more effective management of our working capital, we expect a further improvement in our operating cash flow, leading to net operating cash inflow in the near future.
Our net cash used in operating activities were RMB1,274.7 million, RMB205.5 million, RMB179.2 million and RMB56.7 million for the years ended December 31, 2021, 2022, and 2023 and the six months ended June 30, 2024, respectively.
Summary · p. 13
Despite experiencing a net operating cash outflow in the Track Record Period, we anticipate an improvement in our operating cash flow as we expect to improve our loss making position gradually.
In addition, our net operating cash outflow in 2021 and 2022 amounted to RMB203.7 million and RMB50.0 million, respectively, primarily due to our initiatives to incentivize physician activity and to attract and develop a loyal customer base.
Summary · p. 16
Our net cash used in operating activities decreased significantly for the year ended December 31, 2022 as we gained greater flexibility in setting our customer pricing as we were able to negotiate more favorable procurement terms due to our increased business scale.
For similar reasons, we incurred a net operating cash outflow of RMB31.9 million in 2020.
Summary · p. 18
Our operating cash flow also improved from a net operating cash outflow of RMB31.9 million in 2020 to a net operating cash inflow of RMB178.9 million in 2021.
Summary · p. 18
Nevertheless, our net cash generated from operating activities increased by 19.3% from RMB155.9 million for the six months ended June 30, 2022 to RMB186.0 million for the same period in 2023.
We had negative cash flows from operations in 2019, 2020, 2021 and 2022. Our net cash used in operating activities was RMB277.0 million, RMB70.8 million, RMB868.5 million and RMB456.0 million, respectively, in 2019, 2020, 2021 and 2022.
Financial Information · p. 326
We will also enhance working capital management efficiency through continuously building a stable and collaborative relationship with our suppliers and customers and enhance credit management.
We had net operating cash outflows during the Track Record Period primarily due to our proactive capital expenditure on purchase of devices to support our business growth.
Business · p. 198
For the year ended December 31, 2022, we managed to record a net cash inflow from operations of RMB595.5 million, which fully covered the procurement costs of devices during the same period.
Business · p. 195
Meanwhile, we seek to manage our cash flows by continuing increasing the portion of leased-in devices out of the total number of devices, thereby incurring less upfront capital expenditure.